Therapeutic Radiopharmaceuticals with Current NDAs in the United States*
| Radiopharmaceutical | Brand name | Description | Indication for Therapy | Usual dose range |
|---|---|---|---|---|
| 32P-chromic phosphate | Phospho-coll | Intracavity colloidal injection of β-radiation to treat metastatic effusions | Peritoneal tumor implantsPleural tumor implantsTumor (in ovarian and prostate cancer) | 10–20 mC6–12 mCi.1–.5 mC/g |
| Ibritumomabtiuxetan (111In/90Y) | Zevalin | Monoclonal antibody specific for normal and malignant (lymphoma) B cells | Localization and treatment of non-Hodgkin’s lymphoma | 111In 5 mCi90Y: .3–.4 mCi/kg |
| 131I-tositumomab | Bexxar | Monoclonal antibody specific for normal and malignant (lymphoma) B cells | Localization and treatment of non-Hodgkin’s lymphoma | Dosimetric: 5 mCiTherapy: ∼50–200 mCi |
| 153Sm-lexidronam | Quadramet | Localizes in bone metastases with β-radiation destroying nerve endings | Relief of pain from bone metastases | 1 mCi/kg |
| 131I-sodium iodide | Iodotope | β- (destructive) and γ-radiation localizes in thyroid as it is organized to thyroid hormone | Thyroid function, imaging:Hyperthyroidism oral therapy:Cancer oral therapy: | 5–100 uC4–10 mCi30–150 mCi |
| 32P-sodium phosphate | Localizes in bone with β-radiation damaging bone marrow production and nerve endings | p. vera:CLL, CML:Bone mets: | 3–5 mCi1–3 mCi10–21 mC | |
| 89Sr-chloride | Metastron | Localizes in bone metastases with β-radiation destroying nerve endings | Relief of pain due to bone metastases: | 4 mCi |
↵* List compiled by Mark Soffing, MS, RPh, BCNP, from available sources, including package inserts; personal communication, 2004.